Adaptive Biotechnologies
OrganizationHeard in 1 episode across 1 show since Jun 2026
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company utilizes its proprietary immune profiling platform to read and translate genetic code, developing personalized diagnostics and therapeutics for cancer, autoimmune conditions, and infectious diseases.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 1 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
What experts have said about Adaptive Biotechnologies
2 statements · 1 negative · 1 neutral
Adaptive Biotechnologies shares fell about 6.4% aftermarket.
“shares are down about 6, 6.4% right now.”
Open the episode · SpaceX Jumps, Adaptive Biotechnologies Slides, Dave & Buster's LowerListen at 3:29
Adaptive Biotechnologies plans to offer $250 million in convertible senior notes.
“this company said it plans to offer 250 million convertible senior notes.”
Open the episode · SpaceX Jumps, Adaptive Biotechnologies Slides, Dave & Buster's LowerListen at 3:34
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring Adaptive Biotechnologies, newest first
